The 2020 Top 500 List of Chinese Enterprises was announced, with 10 pharmaceutical companies on the list

"Pharmaceutical Network Industry Dynamics" September 27-28, at the "2020 China 500 Enterprise Summit Forum", the Chinese Enterprise Federation, the China Entrepreneurs Association announced the "2020 China Enterprise 500" list.
the threshold for enterprises to be listed this year is significantly higher, from the annual revenue of enterprises, the 2020 Top 500 Chinese enterprises entry threshold of 35.961 billion yuan, an increase of 3.636 billion yuan over the previous year.
this is the Chinese enterprises top 500 entry threshold for 18 consecutive years to raise.
the operating efficiency of the listed enterprises has also improved.
2020, The top 500 Chinese enterprises achieved operating income of 86.02 trillion yuan, an increase of 6.92 trillion yuan, an increase of 8.75 percent over the previous year, and a net profit of 389.2414 billion yuan, an increase of 360.319 billion yuan, or 10.2 percent.
, Sinopec topped the list with revenue of 2.81 trillion yuan, with State Grid and PetroChina in second and third place, with revenues of 2.65 trillion yuan and 2.62 trillion yuan, respectively.
that the top 500 Chinese enterprises in 2020 are divided into 29 industries.
In terms of the pharmaceutical industry, according to the author is not completely combed, this year a total of 10 pharmaceutical companies on the list, respectively, China Pharmaceutical Group, Shanghai Pharmaceuticals, Guangzhou Pharmaceuticals, Kyushua Tong Pharmaceuticals, Yangzijiang Pharmaceuticals, Hai wang Group, Weigao Group, Taiji Group, Colum Pharmaceuticals and Shi Pharmaceutical Holdings.
, China Pharmaceutical Group, Shanghai Pharmaceuticals and Guangzhou Pharmaceuticals, three pharmaceutical enterprises, in 2019 operating income of more than 100 billion yuan, into the 100 billion club.
Pharmaceutical Group ranked in the top 50 of the top 50 Chinese enterprises in 2020, ranking 37th.
Pharmaceutical Group is a pharmaceutical and health industry group directly managed by SASAC.
owns 11 wholly-owned or controlling subsidiaries and 5 listed companies in China National Pharmaceutical Holdings, China Pharmaceuticals, Tiantan Bio, Hyundai Pharmaceuticals and Consistent Pharmaceuticals.
2019, China Pharmaceutical Group achieved operating income of nearly 50 billion yuan.
Shanghai Pharmaceuticals ranked 118th, and in 2019 the company achieved operating income of 186.566 billion yuan, up 17.27% YoY.
company's main business covers pharmaceutical research and development and manufacturing, distribution and retail industry chain.
has a rich product line, producing approximately 700 drug types throughout the year, covering cardiovascular, immunomodulation, systemic anti-infection, blood and hema production organs and many other fields, with over 35 billion products sold.
, Guangzhou Pharmaceuticals ranked 155th with revenue of 133.051 billion yuan.
company is mainly engaged in Chinese medicine and plant medicine, chemical raw materials and preparations, biological drugs, health products, such as research and development and manufacturing, commercial logistics and distribution and medical and health services business.
addition, Kyushua Tong and Yangzijiang Pharmaceuticals ranked 218th and 237th among the top 500 Chinese enterprises in 2020 with revenues of 99.497 billion yuan and 90.185 billion yuan, respectively.
It is learned that Kyusju Tong is a Western medicine, Chinese medicine, equipment as the main business products, medical institutions, wholesale enterprises, retail pharmacies as the main customer object, and to provide customers with information, logistics and other value-added services enterprise group.
company has a national marketing network and rich upstream and downstream resources, has established a coverage of more than 95% of the country's administrative areas of the marketing network.
Yangzijiang Pharmaceuticals is a large-scale pharmaceutical enterprise group in China that combines industry, research and development, science, industry and trade integration.
companies for major diseases in the study of chemical innovation drugs more than 10, Chinese medicine, biological drugs, high-end pharmaceutical preparations and generic drugs more than 200.
drug research and development areas focus on respiratory anti-allergy, anti-infection, anesthesia analgesia, endocrine, cardiovascular, digestion, Chinese medicine breathing, Chinese medicine digestion and women, tumors, shadow agents, central nervous system and so on.